Sunridge International to Present its Non-Invasive Treatment for Glaucoma to the Southwest Investment Association Conference

FOUNTAIN HILLS, Ariz., March 8 /PRNewswire-FirstCall/ -- Sunridge International, (OTC Bulletin Board: SNDZ) said it will be presenting details of its patented pneumatic trabeculoplasty treatment (PNT) a non-invasive treatment at the upcoming Southwest Investment Association, Inc. (SWIA) Conference on March 13, 2010, at the Westin Stonebriar Hotel in Frisco, Texas.

Making the announcement today, Sunridge International CEO, G. Richard Smith, said, "The Conference provides a timely forum at which to communicate the progress that Sunridge has made in recent months and the inroads it has made in several of the world's major markets.  "Our visit to the Southwest Investment Conference is an important of a robust marketing outreach program to bring the unique advantages our PNT treatment might afford millions of Glaucoma sufferers around the world.  We continue to find after our very successful presentation to the Long Island Investment Banking Group last month, that these meetings like this help us gain awareness throughout the US investment community."

Mr. Smith said that Sunridge International team has much to tell investors.  "Only last week, we won the approval of China's State Food and Drug Administration to market our PNT treatment throughout China, a country which offers our Company huge potential."  He said that after the Texas event, the Sunridge team will be presenting to the San Francisco brokerage community.

The SWIA, was formed to help select companies share information and present investment opportunities to their group of associates, including broker/dealers, investment bankers, investment advisors, analysts, financial managers, capital formation service providers, fund managers, institutions, media and accredited investors.

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension.  The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).

For full details of PNT and its application, we invite you to visit Sunridge International's website at www.sunridgeint.com.

SOURCE Sunridge International